Prevalence and Risk Factors of Prolonged QTc Interval in HIV-Infected Patients: Results of the HIV-HEART Study

REFERENCES

• Tan HL, Hou CJ, Lauer MR, et al. Electrophysiologic mech-anisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med. 1995;122:701–714.
   PubMed Web of Science ®Google Scholar
• Haverkamp W, Hordt M, Chen X, et al. Torsade de pointes. Z KardioL 1993;82:763–774.
   PubMedGoogle Scholar
• Schwartz PJ, Wolf S. QT interval prolongation as predic-tor of sudden death in patients with myocardial infarction. Circulation. 1978;57:1074–1077.
   PubMed Web of Science ®Google Scholar
• Kocheril AG, Bokhari SA, Batsford WP, et al. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin ElectrophysioL 1997;20:2810–2816.
   PubMed Web of Science ®Google Scholar
• Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365:682–686.
   PubMed Web of Science ®Google Scholar
• Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. J Nati Med Assoc. 2005;97:1657–1661.
   PubMed Web of Science ®Google Scholar
• Strauss SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007–2012.
   PubMed Web of Science ®Google Scholar
• Neumann T, Esser S, Potthoff A, et al. HIV-HEART Study Investigative Group. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res. 2007;12:243–248.
   PubMed Web of Science ®Google Scholar
• 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. Guidelines subcommittee. J Hypertens. 1999;17: 151–183.
   PubMed Web of Science ®Google Scholar
• 125L ECG analysis with age and gender specific criteria. Physician's guide. PN 416791004 Revision A. Freiburg: GE Medical Systems IT; 2000.
   Google Scholar
• Willems JL, Abreu-Lima C, Arnaud P, et al. The diag-nostic performance of computer programs for the interpretation of electrocardiograms. N Engl J Med. 1991;325:1767–1773.
   PubMed Web of Science ®Google Scholar
• Froelicher VF, Marcus R, Heidenreich PA. Prognostic value of computer electrocardiography in veteran outpatients. Fed Pract. 2004;3:11–20.
   Google Scholar
• Robbins J, Nelson JC, Rautaharju PM, et al. Associ-ation between the length of the QT interval and mor-tality in the Cardiovascular Health Study. Am J Med. 2003;115:689–694.
   PubMed Web of Science ®Google Scholar
• Moss AJ. Measurement of the QT interval and the risk associated with QTC in interval prolongation: a review. Am J CardioL 1993;72:23–25.
   PubMed Web of Science ®Google Scholar
• Rothman KJ. Modern Epidemiology. Boston, MA: Little, Brown & Company; 1986.
   Google Scholar
• Nordin C, Kohli A, Beca S, et al. Importance of hepatitis coinfection in the development of QT prolongation in HIV-infected patients. J ElectrocardioL 2006;39:199–205.
   PubMed Web of Science ®Google Scholar
• Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodefi-ciency virus infection. Clin Auton Res. 1995;5:48–52.
   PubMedGoogle Scholar
• Silvieri R, Veglio M, Chinaglia A, et al. Prevalence of QT prolongation in a type 1 diabetic population and its association with autonomic neuropathy. Diabet Med. 1993;10:920–924.
   PubMed Web of Science ®Google Scholar
• Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with DL-sotalol. Circulation. 1996;94:2535–2541.
   PubMed Web of Science ®Google Scholar
• Wolbrette DL. Gender differences in the proarrhythmic potential of QT-prolonging drugs. Curr Womens Health Rep. 2002;2:105–159.
   PubMedGoogle Scholar
• Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf. 2001;24:575–585.
   PubMed Web of Science ®Google Scholar
• Busti AJ, Tsikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 2006;7:317–322.
   PubMed Web of Science ®Google Scholar
• Gianotti N, Guffanti M, Galli L, et al. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS. 2007;31:1648–1651.
   Web of Science ®Google Scholar
• Jonker DM, Kenna LA, Leishman D, et al. Apharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human a-ether-a-go-go-related inhibition data. Clin Pharmacol Ther. 2005;77:572–582.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan SY, Goh BC, et al. Mechanism-based inhibi-tion of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44:279–304.
   PubMed Web of Science ®Google Scholar
• Owens RC, Nolin TD. Correspondence: reply to Chinello and Petrosillo. Clin Infect Dis. 2007;44:1389–1391.
   Web of Science ®Google Scholar
• Castillo R, Pedalino RP, El-Sherif N, et al. Efavirenz-associated QT prolongation and torsade de pointes arrhythmia. Ann Pharmacother 200236: 1006–1008.
   Google Scholar
• Gil M, Sala M, Anguera I, et al. QT prolongation and tor-sades de pointes in patients infected with human immuno-deficiency virus and treated with methadone. Am J CardioL 2003;92:995–997.
   PubMed Web of Science ®Google Scholar
• Hrovatin E, Zardo F, Brieda M, et al. Long QT and torsade de pointes in a patient with acquired human immunodefi-ciency virus infection in multitherapy with drugs affecting cytochrome P450. hal Heart J SuppL 2004;5:735–740.
   PubMedGoogle Scholar
• Falconer M, Molloy D, Ingerhaug J, et al. Methadone induced torsade de pointes in a patient receiving antiretro-viral therapy. Ir Med J. 2007;100:631–632.
   PubMedGoogle Scholar
• Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747–753.
   PubMed Web of Science ®Google Scholar
• Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J. 2006;151:1147–1155.
   PubMed Web of Science ®Google Scholar
• Brouillette J, Grandy SA, Jolicoeur P, et al. Cardiac repo-larization is prolonged in CD4C/HIV transgenic mice. J Mol Cell Cardiol. 2007;43: 159–167.
   PubMed Web of Science ®Google Scholar
• Becker K, Gorlach I, Frieling T, et al. Characterization and natural course of cardiac autonomic nervous dysfunction in HIV-infected patients. AIDS. 1997;11:751–757
   PubMed Web of Science ®Google Scholar
• Mittal CM, Wig N, Mishra S, et al. Heart rate variability in human immunodeficiency virus-positive individuals. Int J CardioL 2004;94:1–6.
   PubMed Web of Science ®Google Scholar
• Fliers E, Sauerwein HP, Romijn JA, et al. HIV-associated adipose redistribution syndrome as a selective-autonomic neuropathy. Lancet. 2003;362:1758–1760.
   PubMed Web of Science ®Google Scholar
• Lichenstein K, Balasubramanyam A, Sekhar R, et al. HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther 2007;4:16.
   PubMedGoogle Scholar